Amgen Inc. logo

Amgen Inc.

AMGN
HealthcareNASDAQUnited States
350.85USD+1.08 (+0.31%)

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

The company focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

  • Inflammation: Enbrel (plaque psoriasis, rheumatoid arthritis, psoriatic arthritis), Otezla (plaque psoriasis, psoriatic arthritis, oral ulcers from Behçet’s disease)

  • Oncology & Hematology: KYPROLIS (relapsed/refractory multiple myeloma), BLINCYTO (acute lymphoblastic leukemia), Nplate (thrombocytopenia), Vectibix (metastatic colorectal cancer), IMLYGIC (melanoma), MVASI (biosimilar to Avastin), KANJINTI (biosimilar to Herceptin), AVSOLA (biosimilar to Remicade)

  • Bone Health: Prolia (osteoporosis in postmenopausal women), Xgeva (prevention of skeletal-related events in cancer), EVENITY (osteoporosis treatment)

  • Cardiovascular: Repatha (reduces risk of myocardial infarction, stroke, coronary revascularization), Corlanor (chronic heart failure)

  • Nephrology & Blood Disorders: Aranesp (anemia, low red blood cell count), EPOGEN (anemia in CKD), NEUPOGEN (neutropenia), Parsabiv (secondary hyperparathyroidism), Sensipar/Mimpara (hypercalcemia, SHPT)

  • Neuroscience: Aimovig (migraine prevention)

  • Biosimilars & Other Products: AMGEVITA™ (biosimilar to Humira), additional therapies across autoimmune, oncology, and chronic conditions

Collaborations: Amgen has agreements with Novartis, UCB, Bayer HealthCare, BeiGene, Eli Lilly, Datos Health, and Verastem (e.g., evaluating VS-6766 with sotorasib in KRAS G12C-mutant NSCLC). It also partners with Kyowa Kirin on KHK4083 (atopic dermatitis and autoimmune diseases), and has R&D collaborations with Neumora Therapeutics and Plexium.

It serves healthcare providers such as physicians, clinics, dialysis centers, hospitals, and pharmacies, and distributes through pharmaceutical wholesalers and direct-to-consumer channels.

Amgen was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen's Business Strategy

Amgen's strategy is focused on discovering, developing, manufacturing, and delivering innovative human therapeutics, leveraging its deep expertise in biotechnology and molecular biology to address serious illnesses. The company concentrates its efforts in key therapeutic areas including Oncology, Inflammation, General Medicine (encompassing cardiovascular and bone health),…

Available on Finplify

Free account required

Sign up free

Our Take on Amgen

Pros:

Biologics & Biotechnology Leader: Amgen is one of the world’s largest biotech companies, with core strengths in inflammation, oncology, nephrology, and cardiovascular disease. Its deep experience in biologics supports high-margin, complex therapies with long life cycles.

Diversified Product Portfolio: The company’s portfolio includes…

Available on Finplify

Free account required

Sign up free

Company Details

Exchange
NASDAQ
Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert A. Bradway
Employees
28,000
IPO Date
1983-06-17
ISIN
US0311621009
Website
amgen.com

Key Metrics

Market Cap
189.13BUSD
P/E Ratio (TTM)
24.45
Net Profit Margin
20.97%
Debt / Asset Ratio
0.60
Dividend Yield (TTM)
2.76%
Volume
144,892
Avg Volume
2.95M
Shares Outstanding
538.48M
Free Float
99.80%
β Beta
0.47
52W Range
261.4 - 391.3

Fundamental Analysis

Proprietary 5-category scoring system

Score Fingerprint

Section Scores

Profitability
4.6/5Excellent
Liquidity
3.0/5Average
Leverage
1.5/5Poor
Cash Flow
4.5/5Excellent
Valuation
3.7/5Good

Full Breakdown & Peer Ranking

See the detailed score for every metric and how this stock ranks against its sector peers

Unlock for free
Free to join

Unlock the full research on Amgen

Get the full fundamental score breakdown, business strategy, our investment take, live charts and AI-powered briefings. All in one ad-free workspace.

300+ Curated Stocks

A hand-picked universe of world-class businesses across every major market and sector.

AI Analyst Briefings

Deploy your own AI analyst that monitors your portfolio and delivers daily intelligence reports.

Proprietary Fundamentals

Five-category scoring for every stock — profitability, liquidity, leverage, cash flow, and valuation.